Description

In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.

Faculty

• Thomas Berg (Moderator)
• Katie Kelley (Faculty)
• Daniela Sia (Faculty)
• Juan Valle (Faculty)

This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.

Related episodes

• EASL Studio S5E13: Basics in decision-making for liver cancer treatment
• EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
• EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
• EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In this episode, the panellists evaluate past efforts, current trials, and the evolving landscape of HBV cure research. They also weigh the patient-friendliness of these strategies, exploring potential pathways to a cure. How will the landscape of trials and research methodologies evolve in the future to facilitate this quest?

Faculty

• Ahmed Elsharkawy (Moderator)
• Markus Cornberg (Faculty)
• Dickens Theodore (GSK Representative)
• Su Wang (Faculty)

This EASL Studio is supported by GSK.

Related episodes:

• EASL Studio from EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challenges
• EASL Studio S4E1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?
• EASL Studio S3E9: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B —Who will be the winner, if at all?
• EASL Studio from ILC 2022: HBV/HDV Roundtable: HBV and HDV drug development – Where do we stand and where are we going?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.

Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!

Faculty

• Sven Francque (Moderator)
• Willem Pieter Brouwer (Faculty)
• Cyrielle Caussy (Faculty)
• Dimitris Papamargaritis (Faculty)

This episode is scheduled following the United Kingdom’s National Obesity Awareness Week.

Related episodes:

• EASL Studio S5E7: Why bother with diet and exercise when an injection will suffice?
• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S2E2: Fats or carbs, who is the real villain?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.